Find our statements and responses to events affecting people with cystic fibrosis (CF) here.
In this section
If you need to get in touch with our press team, please contact email@example.com or call on 020 3795 2193.
Joint letter with Macmillan Cancer Support and other charities to The Rt Hon Michael Gove MP in the Cabinet Office, calling for clearer guidance on shielding and what the future may hold as restrictions are eased (28 May 2020)
Response to Environment, Food and Rural Affairs Committee Inquiry into food supply during the Coronavirus pandemic (20 May 2020)
Letter to Rishi Sunak from David Ramsden regarding financial support for people with CF during coronavirus (27 March 2020)
Letters to Arlene Foster, the Department for Environment, Food and Rural Affairs, Mark Drakeford and Nicola Sturgeon regarding plans for social shielding (27 March 2020)
Letter to UK supermarkets regarding access to food for people with CF during the coronavirus outbreak (26 March 2020)
The Cystic Fibrosis Trust's Safeguarding policy statement (November 2019)
Letter to Petitions Committee from the Cystic Fibrosis Trust (11 June 2019)
Letter from David Ramsden, Chief Executive, to Dr Sarah Wollaston MP in response to NHS, NICE and Vertex correspondence (4 June 2019)
Statement on the NHS offer to Vertex for Orkambi and Symkevi (23 May 2019)
Letter from Ian Austin MP to Prime Minister Theresa May (16 May 2019)
Marking the anniversary of PM Theresa May wishing for a "speedy resolution" on Orkambi (16 May 2019)
Cystic Fibrosis Trust calls for immediate access to life-saving drugs (7 March 2019)
Creon shortage - Oxfordshire & Surrey (26 July 2018)
Mylan announces temporary Creon shortage (12 June 2018)
Cystic Fibrosis Trust appoints David Ramsden as new Chief Executive (12 October 2016)
The Cystic Fibrosis Trust's response to the NHS England decision that complex heart surgery should no longer be provided at the Royal Brompton & Harefield NHS Foundation Trust (8 July 2016).
The Cystic Fibrosis Trust's response to the NHS England funding decision for Ivacaftor (Kalydeco) for two to five year olds (4 August 2016).
We fund research to tackle some of the most pressing issues in CF today. Find out how your donations are making a difference.
Cystic fibrosis, or CF, affects the lungs, digestive system and other organs, and there are around 10,500 people living with it in the UK.
Get in touch with us to speak to someone on our Helpline, find out about an event or speak to our Press Team.